Chemotherapy and Radiotherapy utilize DNA-PK and PARP inhibitors to sensitize cancer cells, however these inhibitors have so far only been limited to homologous recombination repair deficient tumors, exploiting synthetic lethality.
In the study “Sensitizing ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP)” Britta Vormoor, et al tested single agent PARP and DNA-PK inhibitors in Ewing sarcoma cell lines by performing growth inhibition and clonogenic assays in the Xstrahl CIX3.
The study concluded that whilst DNA-PK and PARP inhibitors are efficient inhibitors for Ewing sarcoma, the sensitivity in vitro was not matched in vivo. Future study is required to enable these inhibitors to be used with a combination radiotherapy treatment for study in clinical trials.
This Xstrahl In Action was adapted from a article found on a National Library of Medicine website.
